Wockhardt Ltd.
NSE: WOCKPHARMA · Pharmaceuticals
Snapshot
Unlock Wockhardt Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Wockhardt Limited is a pharmaceutical and biotechnology company that manufactures and markets active pharmaceutical ingredients, formulations, bio-similars, and vaccines. The company focuses on developing molecules for infectious diseases and provides contract manufacturing and research services.
Business Model
The company generates revenue through the sale of its proprietary pharmaceutical products, biopharmaceuticals, and vaccines, alongside providing contract manufacturing services for sterile injectables and lyophilization.
Growth Outlook
Growth is primarily driven by the development of its pipeline of infectious disease molecules and the expansion of its biopharmaceutical portfolio, including insulin analogs and recombinant products.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent quality standards and inspections by international regulatory bodies like the US FDA.
- R&D Success. The long-term growth strategy relies heavily on the successful clinical development and commercialisation of its proprietary infectious disease molecules.
- Geopolitical and Currency Risk. As an exporter with operations in multiple international markets, the company is exposed to currency fluctuations and changing trade policies.
- Market Competition. The pharmaceutical sector is highly competitive, with pricing pressures on generic formulations and biopharmaceuticals impacting profit margins.
Start your research today
Unlock AI insights, financials, peers and live data on Wockhardt Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹3,564 Cr
TTM · consolidated
NET PROFIT
₹414 Cr
TTM · consolidated
EPS
₹25.20
TTM · consolidated
RETURN ON EQUITY
8.9%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
10.4%
TTM · consolidated
P/E
82.9x
Q1 FY27 · consolidated
EV/EBITDA
40.1x
Q1 FY27 · consolidated
EBITDA MARGIN
25.1%
TTM · consolidated
NET PROFIT MARGIN
11.5%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.4x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Wockhardt Ltd.WOCKPHARMA | ₹33,940 Cr | 82.88 | 40.10 | 18.4% | 25.1% | 8.9% | 10.4% | +41.5% |
Emcure Pharmaceuticals Ltd.EMCURE | ₹36,559 Cr | 36.13 | 18.90 | 18.4% | 20.6% | 21.7% | 27.3% | +40.6% |
Sai Life Sciences Ltd.SAILIFE | ₹33,605 Cr | 92.27 | 47.96 | — | 31.2% | 15.7% | 19.8% | +86.7% |
Rubicon ResearchRUBICON | ₹29,245 Cr | 99.68 | 63.32 | — | 23.9% | 22.4% | 27.6% | — |
Neuland Laboratories Ltd.NEULANDLAB | ₹29,073 Cr | 58.41 | 36.78 | 78.3% | 33.5% | 29.3% | 35.4% | +55.1% |
Piramal Pharma Ltd.PPLPHARMA | ₹28,520 Cr | -90.39 | 26.16 | 0.8% | 13.6% | -3.9% | 1.4% | +7.7% |
As of Q1 FY27
Financials
Wockhardt Ltd.
NSE: WOCKPHARMA · Pharmaceuticals
Snapshot
Unlock Wockhardt Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Wockhardt Limited is a pharmaceutical and biotechnology company that manufactures and markets active pharmaceutical ingredients, formulations, bio-similars, and vaccines. The company focuses on developing molecules for infectious diseases and provides contract manufacturing and research services.
Business Model
The company generates revenue through the sale of its proprietary pharmaceutical products, biopharmaceuticals, and vaccines, alongside providing contract manufacturing services for sterile injectables and lyophilization.
Growth Outlook
Growth is primarily driven by the development of its pipeline of infectious disease molecules and the expansion of its biopharmaceutical portfolio, including insulin analogs and recombinant products.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent quality standards and inspections by international regulatory bodies like the US FDA.
- R&D Success. The long-term growth strategy relies heavily on the successful clinical development and commercialisation of its proprietary infectious disease molecules.
- Geopolitical and Currency Risk. As an exporter with operations in multiple international markets, the company is exposed to currency fluctuations and changing trade policies.
- Market Competition. The pharmaceutical sector is highly competitive, with pricing pressures on generic formulations and biopharmaceuticals impacting profit margins.
Start your research today
Unlock AI insights, financials, peers and live data on Wockhardt Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹3,564 Cr
TTM · consolidated
NET PROFIT
₹414 Cr
TTM · consolidated
EPS
₹25.20
TTM · consolidated
RETURN ON EQUITY
8.9%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
10.4%
TTM · consolidated
P/E
82.9x
Q1 FY27 · consolidated
EV/EBITDA
40.1x
Q1 FY27 · consolidated
EBITDA MARGIN
25.1%
TTM · consolidated
NET PROFIT MARGIN
11.5%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.4x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27